Literature DB >> 19995707

Mutations in the KRAS gene in ovarian tumors.

Bozena Dobrzycka1, Sławomir J Terlikowski, Oksana Kowalczuk, Wiesława Niklińska, Lech Chyczewski, Marek Kulikowski.   

Abstract

RAS genes are the most frequently mutated oncogenes detected in human cancer. In this study we analyzed the presence of mutations at codon 12 of the KRAS gene in 78 women with ovarian tumor, including 64 invasive ovarian cancers and 14 borderline ovarian tumors, using an RFLP-PCR technique and we evaluated whether such alterations were associated with the selected clinicopathological parameters of the patients. KRAS codon 12 gene mutations were found in 6,2% of ovarian cancer tissue and in 14,3% of the borderline ovarian tumor. KRAS mutations were found with a significantly higher frequency in mucinous and borderline tumors compared to serous tumors (p<0,01). Mutation frequency was correlated with the histological type of tumor, but not with stage, grade or patients age.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19995707     DOI: 10.2478/v10042-009-0039-6

Source DB:  PubMed          Journal:  Folia Histochem Cytobiol        ISSN: 0239-8508            Impact factor:   1.698


  5 in total

Review 1.  PAR-4 as a possible new target for pancreatic cancer therapy.

Authors:  Asfar S Azmi; Philip A Philip; Syed F Zafar; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Expert Opin Ther Targets       Date:  2010-06       Impact factor: 6.902

2.  An integrative approach to identifying cancer chemoresistance-associated pathways.

Authors:  Shih-Yi Chao; Jung-Hsien Chiang; A-Mei Huang; Woan-Shan Chang
Journal:  BMC Med Genomics       Date:  2011-03-24       Impact factor: 3.063

3.  Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.

Authors:  Katarzyna M Terlikowska; Bozena Dobrzycka; Anna M Witkowska; Beata Mackowiak-Matejczyk; Tomasz Kamil Sledziewski; Maciej Kinalski; Slawomir J Terlikowski
Journal:  J Ovarian Res       Date:  2016-07-19       Impact factor: 4.234

4.  Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.

Authors:  Yi-Ju Lee; Ming-Yung Lee; Alexandra Ruan; Chi-Kuan Chen; Hao-Ping Liu; Chau-Jong Wang; Wan-Ru Chao; Chih-Ping Han
Journal:  Oncotarget       Date:  2016-12-13

Review 5.  Activation of STAT3 and STAT5 Signaling in Epithelial Ovarian Cancer Progression: Mechanism and Therapeutic Opportunity.

Authors:  Chin-Jui Wu; Vignesh Sundararajan; Bor-Ching Sheu; Ruby Yun-Ju Huang; Lin-Hung Wei
Journal:  Cancers (Basel)       Date:  2019-12-19       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.